Skip to main content

Accelerated Approval Granted to Tisagenlecleucel for Treatment of Relapsed or Refractory Follicular Lymphoma

The FDA has given accelerated approval to tisagenlecleucel (Kymriah®, Novartis) for treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL) within six months of receiving two or more lines of systemic therapy or if the patient relapsed after an autologous hematopoietic stem cell transplant. "Follicular lymphoma is a common non-Hodgkin lymphoma that is generally considered indolent, but the disease remains incurable, and the majority of patients eventually relapse," wrote...

Continue reading

Interpreting the CAR T Results of Tisagenlecleucel for Relapsed/Refractory Non-Hodgkin Lymphoma: Michael R. Bishop, MD

Michael Bishop, MD.

In the phase 3 BELINDA trial, a team of researchers led by Dr. Michael Bishop, Director of Hematopoietic Stem Cell Transplantation at the University of Chicago Medicine, investigated tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, as second-line treatment for patients with relapsed/refractory aggressive non-Hodgkin lymphoma. The investigators found that tisa-cel did not improve event-free survival compared with the standard of care, which consisted of platinum-based chemotherapy followed by autologous stem cell transplant in responders. Dr. Bishop recently presented the results of the trial at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia. In this interview with Oncology Data Advisor, he explains how these results should be interpreted and their significance for the future of CAR T-cell therapy.  

Continue reading

CAR T-Cell Therapies: Survey of Oncology Nurses Reveals Much to Be Learned

​Chimeric antigen receptor (CAR) T-cell therapy is a form of immunotherapy in which a patient's own T cells are collected and genetically altered to target cancer cells. Although CAR T-cell therapies have shown encouraging results in patients with acute lymphoblastic leukemia and B-cell lymphomas, they are associated with several serious adverse events, including cytokine release syndrome, neurotoxicity, tumor lysis syndrome, and graft-versus-host disease.  In light of the growing use of CA...

Continue reading